The FDA approved an oral pancreatic cancer therapy, daraxonrasib, after results showed it nearly doubled survival, according to reporting tied to Sylvester Comprehensive Cancer Center research. The approval adds another targeted option for a disease where treatment advances remain incremental. Separately, a pooled analysis suggests liver metastases worsen outcomes for patients receiving chemotherapy in pancreatic cancer but do not show a similar negative signal for immune checkpoint inhibitor regimens. That contrast may refine how clinicians stratify patients by metastatic pattern when considering systemic therapy. Taken together, the approval and emerging biomarker contrasts emphasize a growing split between chemotherapy resistance patterns and immunotherapy responsiveness in pancreatic cancer biology.